Despite recent sales growth, Mallinckrodt keeps financial options—including bankruptcy—on the table

Despite recent sales growth, Mallinckrodt keeps financial options—including bankruptcy—on the table

Source: 
Fierce Pharma
snippet: 

Despite a return to revenue growth in 2023’s second quarter, troubled Mallinckrodt continues to weigh its financial options, according to CEO Siggi Olafsson. Among them is a new bankruptcy bid that could get the company off the hook for more than $1 billion in opioid settlement payments.